Skip to main content
Marco Ruella, MD, Hematology, Philadelphia, PA, Hospital of the University of Pennsylvania

MarcoRuellaMD

Hematology • Philadelphia, PA

Hematologic Oncology

Assistant Professor of Medicine and Scientific Director, Lymphoma Program

Join to view full profile

Dr. Ruella is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ruella's full profile

Already have an account?

  • Office

    3400 Civic Center Blvd
    Perelman Center for Advanced Medicine, SPE 8-112
    Philadelphia, PA 19104
    Phone+1 215-746-4880
  • Is this information wrong?

Education & Training

  • Penn Medicine
    Penn MedicinePost-Doctoral Fellowship, post doctoral fellowship, 2012 - 2018
  • University of Torino
    University of TorinoSpecialty in Hematology, Clinical Hematology and Cell Therapy, cum Laude, 2008 - 2012
  • University of Torino Faculty of Medicine
    University of Torino Faculty of MedicineClass of 2007

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2018 - 2024

Publications & Presentations

PubMed

Journal Articles

  • Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B Cell  
    Vijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
  • Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer  
    Nathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports

Abstracts/Posters

  • A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
    Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
    Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
    Marco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Authored Content

  • The Quest To Cure CLL: “Remarkable” Results With New StrategySeptember 2023

Press Mentions

  • Penn Medicine at the 2022 ASH Meeting
    Penn Medicine at the 2022 ASH MeetingDecember 8th, 2022
  • Where Does CAR T-cell Cancer Therapy Stand After Its FDA Approval?
    Where Does CAR T-cell Cancer Therapy Stand After Its FDA Approval?August 4th, 2021
  • New CAR T-cell Therapy Uses Shorter Linker, Leading to More Potent Therapy for ALL
    New CAR T-cell Therapy Uses Shorter Linker, Leading to More Potent Therapy for ALLJuly 20th, 2021
  • Join now to see all

Hospital Affiliations

Dr. Marco Ruella, Dr. Marco Ruella, MD, Dr. M Ruella